Skip to main content
Verubecestat, atabecestat don't curb Alzheimer's progression

People with impaired memory and increased brain amyloid levels who received verubecestat, especially those who were given larger doses, had higher estimated mean changes on the Clinical Dementia Rating Scale Sum of Boxes between baseline and 104 weeks, suggesting worse outcomes, compared with those who took placebo, according to a study in The New England Journal of Medicine. Another study in the same journal also showed greater reductions in Preclinical Alzheimer's Cognitive Composite scores after six months among those who received atabecestat, particularly those who took higher doses, compared with the placebo group.

Full Story: